-
Something wrong with this record ?
The influence of coffee intake and genetics on adenosine pathway in rheumatoid arthritis
T. Soukup, K. Hloch, M. Doseděl, JD. Tebbens, J. Nekvindová, Š. Šembera, T. Veleta, P. Pávek, I. Barvík
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2000-02-01 to 2020-12-31
Health & Medicine (ProQuest)
from 2000-02-01 to 2020-12-31
PubMed
32615857
DOI
10.2217/pgs-2020-0042
Knihovny.cz E-resources
- MeSH
- Adenosine genetics metabolism MeSH
- Antirheumatic Agents metabolism therapeutic use MeSH
- Adult MeSH
- Polymorphism, Single Nucleotide genetics MeSH
- Coffee adverse effects metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Methotrexate metabolism therapeutic use MeSH
- Cross-Sectional Studies MeSH
- Receptor, Adenosine A2A genetics MeSH
- Arthritis, Rheumatoid drug therapy genetics metabolism MeSH
- Signal Transduction drug effects physiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Aim: We studied the influence of coffee consumption on the therapeutic effect of methotrexate (MTX) in patients with rheumatoid arthritis (RA) sorted according to ADORA2A genotypes. Patients & methods: 82 RA patients were dichotomized according to caffeine intake with a threshold of 700 mg/week. Disease activity score 28 (DAS28) was applied (>3.2: high; <3.2: low or remission). Patients were genotyped using quantitative PCR allelic discrimination. Results: We found significantly higher risk of RA in patients with higher caffeine intake and the CT genotype of ADOARA2A rs2298383, rs3761422 and rs2267076 SNPs. The CC genotype of ADORA2A rs2236624 SNP in patients with lower caffeine intake treated with MTX is significantly protective. Conclusion:ADORA2A genotypes and coffee intake influence risk of RA and efficacy of it MTX treatment.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020418
- 003
- CZ-PrNML
- 005
- 20210830102119.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/pgs-2020-0042 $2 doi
- 035 __
- $a (PubMed)32615857
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Soukup, Tomáš $u 2nd Department of Internal Medicine - Gastroenterology, Division of Rheumatology, Charles University, Faculty of Medicine & University Hospital in Hradec Kralove, Hradec Kralove, 50005, Czech Republic
- 245 14
- $a The influence of coffee intake and genetics on adenosine pathway in rheumatoid arthritis / $c T. Soukup, K. Hloch, M. Doseděl, JD. Tebbens, J. Nekvindová, Š. Šembera, T. Veleta, P. Pávek, I. Barvík
- 520 9_
- $a Aim: We studied the influence of coffee consumption on the therapeutic effect of methotrexate (MTX) in patients with rheumatoid arthritis (RA) sorted according to ADORA2A genotypes. Patients & methods: 82 RA patients were dichotomized according to caffeine intake with a threshold of 700 mg/week. Disease activity score 28 (DAS28) was applied (>3.2: high; <3.2: low or remission). Patients were genotyped using quantitative PCR allelic discrimination. Results: We found significantly higher risk of RA in patients with higher caffeine intake and the CT genotype of ADOARA2A rs2298383, rs3761422 and rs2267076 SNPs. The CC genotype of ADORA2A rs2236624 SNP in patients with lower caffeine intake treated with MTX is significantly protective. Conclusion:ADORA2A genotypes and coffee intake influence risk of RA and efficacy of it MTX treatment.
- 650 _2
- $a adenosin $x genetika $x metabolismus $7 D000241
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antirevmatika $x metabolismus $x terapeutické užití $7 D018501
- 650 _2
- $a revmatoidní artritida $x farmakoterapie $x genetika $x metabolismus $7 D001172
- 650 _2
- $a káva $x škodlivé účinky $x metabolismus $7 D003069
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a methotrexát $x metabolismus $x terapeutické užití $7 D008727
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a jednonukleotidový polymorfismus $x genetika $7 D020641
- 650 _2
- $a receptor adenosinový A2A $x genetika $7 D043705
- 650 _2
- $a signální transdukce $x účinky léků $x fyziologie $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hloch, Karel $u Department of Social & Clinical Pharmacy, Charles University, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, 50005, Czech Republic
- 700 1_
- $a Doseděl, Martin $u Department of Social & Clinical Pharmacy, Charles University, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, 50005, Czech Republic
- 700 1_
- $a Tebbens, Jurjen Duintjer $u Department of Biophysics & Physical Chemistry, Charles University, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, 50005, Czech Republic
- 700 1_
- $a Nekvindová, Jana $u University Hospital Hradec Kralove, Institute of Clinical Biochemistry and Diagnostics, Hradec Kralove, 50005, Czech Republic
- 700 1_
- $a Šembera, Štěpán $u 2nd Department of Internal Medicine - Gastroenterology, Division of Rheumatology, Charles University, Faculty of Medicine & University Hospital in Hradec Kralove, Hradec Kralove, 50005, Czech Republic
- 700 1_
- $a Veleta, Tomáš $u Department of Emergency Medicine, Charles University, University Hospital in Hradec Kralove, Hradec Kralove, 50005, Czech Republic
- 700 1_
- $a Pávek, Petr $u Department of Pharmacology & Toxicology & Centre for Drug Development, Charles University, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, 50005, Czech Republic
- 700 1_
- $a Barvík, Ivan $u Faculty of Mathematics & Physics, Institute of Physics, Charles University, Prague, 12116, Czech Republic
- 773 0_
- $w MED00008477 $t Pharmacogenomics $x 1744-8042 $g Roč. 21, č. 11 (2020), s. 735-749
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32615857 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102119 $b ABA008
- 999 __
- $a ok $b bmc $g 1691068 $s 1140864
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 21 $c 11 $d 735-749 $e 20200703 $i 1744-8042 $m Pharmacogenomics $n Pharmacogenomics $x MED00008477
- LZP __
- $a Pubmed-20210728